HER2-Negative Breast Cancer Clinical Pipeline Witnesses Significant Growth as 70+ Companies Accelerate Therapeutic Innovation | DelveInsight

HER2-Negative Breast Cancer companies include Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co., Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, among others.
DelveInsight's "HER2-Negative Breast Cancer Pipeline Insight 2026" report delivers in-depth intelligence on more than 70 companies and over 75 pipeline therapies shaping the HER2-negative breast cancer landscape. The report offers detailed evaluations of pipeline candidates, covering both clinical and preclinical stages. Additionally, it analyzes therapies based on product classification, development phase, route of administration, and molecular composition, while also shedding light on discontinued and inactive assets within this segment.

Access DelveInsight's detailed HER2-Negative Breast Cancer Pipeline Report here: https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight

Key Highlights from the HER2-Negative Breast Cancer Pipeline Report

* On February 23, 2026, Institut Curie initiated a Phase II clinical study investigating the combination of tucatinib (a HER2 tyrosine kinase inhibitor) and trastuzumab (a HER2-targeted monoclonal antibody) in patients with metastatic or unresectable HER2 non-amplified breast cancer carrying activating ERBB3 mutations. The study aims to validate the clinical relevance of ERBB3 mutations, with patients receiving the combination therapy in 3-week cycles.
* On February 19, 2026, Merck Sharp & Dohme LLC announced a Phase III randomized, open-label trial assessing the efficacy and safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) followed by Carboplatin/Paclitaxel versus chemotherapy, both combined with pembrolizumab, as neoadjuvant treatment for high-risk early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer.
* DelveInsight's analysis highlights a highly competitive and evolving pipeline landscape, with over 70 companies actively developing more than 75 therapies targeting HER2-negative breast cancer.
* Key industry participants include Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co., Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, among others.
* Notable therapies under development include Doxorubicin, Cyclophosphamide, Utidelone in combination with Bevacizumab, Capecitabine, Carboplatin, Cisplatin, and additional candidates.

Explore DelveInsight's comprehensive HER2-Negative Breast Cancer pipeline analysis for detailed insights into clinical trials and emerging therapies: https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight

Report Overview

The HER2-Negative Breast Cancer Pipeline Report offers a comprehensive overview of the disease, current pipeline landscape, and therapeutic advancements. It also identifies key unmet clinical needs and opportunities for innovation in HER2-negative breast cancer treatment.

HER2-Negative Breast Cancer: Disease Overview

Breast cancer remains the most prevalent cancer among women worldwide and is a leading cause of cancer-related mortality. Approximately 5% of patients present with distant metastases at diagnosis, while nearly 30% of early-stage patients eventually develop metastatic disease. Although metastatic breast cancer is not curable, advancements in novel therapies have significantly improved survival outcomes.

Treatment strategies for metastatic breast cancer primarily focus on extending survival and enhancing patients' quality of life by effectively managing symptoms. Personalized treatment approaches are essential, as therapeutic strategies vary based on individual patient profiles. HER2-negative breast cancer is characterized by the absence of overexpression of the HER2 protein in tumor cells.

Emerging Drug Profiles in HER2-Negative Breast Cancer

Giredestrant - Genentech

Giredestrant is an investigational oral small molecule designed as a selective estrogen receptor degrader (SERD). It targets estrogen receptors by inhibiting estrogen binding and disrupting receptor signaling. Preclinical findings indicate strong oral bioavailability and effectiveness in inhibiting both wild-type and mutant estrogen receptors, reducing gene expression linked to tumor growth. The therapy is currently in Phase III clinical development.

Inavolisib - Genentech

Inavolisib is a targeted small molecule inhibitor selectively designed to block mutant PI3K activity. It demonstrates enhanced potency against mutant PI3K compared to wild-type variants and exhibits reduced activity against other PI3K isoforms. The drug inhibits downstream signaling by blocking phosphorylation processes and also promotes degradation of mutant PI3K proteins. It is presently in Phase III trials.

CX-2009 (Praluzatamab Ravtansine) - CytomX Therapeutics

CX-2009 is a conditionally activated antibody-drug conjugate (ADC) targeting CD166. It combines a humanized monoclonal antibody with a cytotoxic DM4 payload and utilizes Probody Registered technology to selectively activate within the tumor microenvironment. This mechanism minimizes off-target toxicity. The therapy is currently being evaluated in Phase II studies.

H3B-6545 - H3 Biomedicine

H3B-6545 is an orally administered selective estrogen receptor covalent antagonist (SERCA) designed for ER-positive, HER2-negative metastatic breast cancer. It demonstrates activity against both wild-type and mutant ER, including variants resistant to standard therapies, offering potential to address unmet clinical needs. The candidate is in Phase II development.

RGT-419B - Regor Therapeutics

RGT-419B is a next-generation CDK inhibitor optimized for broader kinase targeting. Preclinical data indicate its effectiveness in suppressing proliferation in ER-positive breast cancer cells resistant to CDK4/6 inhibitors. Its efficacy is further enhanced when used in combination with SERDs or PI3K inhibitors. The drug is currently in Phase I trials.

Explore DelveInsight's expert insights on unmet needs in HER2-Negative Breast Cancer today : https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight

Key Insights from the HER2-Negative Breast Cancer Pipeline Report

* The report offers detailed profiling of companies actively developing therapies for HER2-negative breast cancer, along with a consolidated view of their respective pipelines.
* It categorizes therapeutic candidates based on development stages, including early, mid, and late phases.
* The analysis covers both active and inactive (discontinued or dormant) pipeline projects.
* It provides segmentation of drugs based on development phase, route of administration, molecular targets, therapy type (monotherapy vs combination), mechanism of action, and molecular class.
* It includes a comprehensive evaluation of partnerships, licensing deals, and funding activities supporting pipeline progression.

Leading Companies in HER2-Negative Breast Cancer

Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co., Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, and others.

Therapeutic Segmentation by Route of Administration

* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical

Classification by Molecule Type

* Monoclonal antibodies
* Peptides
* Polymers
* Small molecules
* Gene therapies

Download DelveInsight's latest report to gain actionable insights into emerging therapies, market drivers, barriers, and future outlook in HER2-negative breast cancer : https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight

Scope of the HER2-Negative Breast Cancer Pipeline Report

* Coverage: Global
* Companies: Includes major players such as Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, and others
* Therapies: Doxorubicin, Cyclophosphamide, Utidelone + Bevacizumab, Capecitabine, Carboplatin, Cisplatin, among others
* Product Types: Monotherapy, Combination therapy, and hybrid approaches
* Development Stages: Discovery, Preclinical, Phase I, Phase II, Phase III

Access DelveInsight's exclusive HER2-Negative Breast Cancer pipeline insights today : https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight

Table of Contents

* Introduction
* Executive Summary
* Disease Overview: HER2-Negative Breast Cancer
* Pipeline Therapeutics
* Therapeutic Assessment
* DelveInsight Analytical Perspective
* Late-Stage Products (Phase III) - Giredestrant (Genentech)
* Mid-Stage Products (Phase II) - CX-2009 (CytomX Therapeutics)
* Early-Stage Products (Phase I) - RGT-419B (Regor Therapeutics)
* Preclinical and Discovery Candidates
* Inactive Pipeline Products
* Key Companies and Therapies
* Unmet Needs
* Market Drivers and Barriers
* Future Outlook and Conclusions
* Analyst Insights
* Appendix
* About DelveInsight

About DelveInsight

DelveInsight is a globally recognized healthcare market research and consulting firm dedicated to delivering high-quality market intelligence and strategic insights. With a team of experienced professionals and deep expertise in life sciences and healthcare, the company provides tailored research solutions to support informed decision-making. Partner with DelveInsight to access accurate, real-time insights and stay ahead in a competitive market landscape.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=her2negative-breast-cancer-clinical-pipeline-witnesses-significant-growth-as-70-companies-accelerate-therapeutic-innovation-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.